You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 21, December 1, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (415)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Cerebrovascular Disease
 •Randomized Controlled Trial
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset

The ATLANTIS Study: A Randomized Controlled Trial

Wayne M. Clark, MD; Stanley Wissman, MD; Gregory W. Albers, MD; Jack H. Jhamandas, MD, PhD; Kenneth P. Madden, MD, PhD; Scott Hamilton, PhD; for the ATLANTIS Study Investigators

JAMA. 1999;282:2019-2026.

Context  Recombinant tissue-type plasminogen activator (rt-PA) improves outcomes for patients with acute ischemic stroke, but current approved use is limited to within 3 hours of symptom onset. This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset.

Objective  To test the efficacy and safety of rt-PA in patients with acute ischemic stroke when administered between 3 and 5 hours after symptom onset.

Design  The Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study is a phase 3, placebo-controlled, double-blind randomized study conducted between December 1993 and July 1998, with up to 90 days of follow-up.

Setting  One hundred forty university and community hospitals in North America.

Patients  An intent-to-treat population of 613 acute ischemic stroke patients was enrolled, with 547 of these treated as assigned within 3 to 5 hours of symptom onset. A total of 39 others were treated within 3 hours of symptom onset, 24 were treated more than 5 hours after symptom onset, and 3 never received any study drug.

Intervention  Administration of 0.9 mg/kg of rt-PA (n = 272) or placebo (n = 275) intravenously over 1 hour.

Main Outcome Measures  Primary efficacy was an excellent neurologic recovery at day 90 (National Institutes of Health Stroke Scale [NIHSS] score of <=1); secondary end points included excellent recovery on functional outcome measures (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at days 30 and 90. Serious adverse events were also assessed.

Results  In the target population, 32% of the placebo and 34% of rt-PA patients had an excellent recovery at 90 days (P = .65). There were no differences on any of the secondary functional outcome measures. In the first 10 days treatment with rt-PA significantly increased the rate of symptomatic intracerebral hemorrhage (ICH) (1.1% vs 7.0% [P<.001]), a symptomatic ICH (4.7% vs 11.4% [P = .004]), and fatal ICH (0.3% vs 3.0% [P<.001]). Mortality at 90 days was 6.9% with placebo and 11.0% with rt-PA (P = .09). Results in the intent-to-treat population were similar.

Conclusions  This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treatment. These results do not support the use of intravenous rt-PA for stroke treatment beyond 3 hours.


Author Affiliations: Oregon Stroke Center, Portland (Dr Clark); Stucky Research Center, Fort Wayne, Ind (Dr Wissman); Stanford Stroke Center, Stanford University, Palo Alto, Calif (Dr Albers); Department of Neurology, University of Alberta, Edmonton (Dr Jhamandas); Marshfield Clinic, Marshfield, Wis (Dr Madden); and Genentech Inc, South San Francisco, Calif (Dr Hamilton). Dr Wissman is deceased.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Outcomes of Ancrod in Acute Ischemic Stroke
Darren Orbach, David Levine, Jean-Marc Orgogozo, Marc Verstraete, Richard Kay, Michael Hennerici, Gian-Luigi Lenzi, David G. Sherman, and David E Levy
JAMA. 2000;284(15):1926-1927.
EXTRACT | FULL TEXT  

RELATED ARTICLE

December 1, 1999
JAMA. 1999;282(21):2087-2088.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Guidelines For Extending the Tissue Plasminogen Activator Treatment Window for Ischemic Stroke
Asimos
Stroke 2009;40:e633-e633.
FULL TEXT  

Expanding Recombinant Tissue Plasminogen Activator Time Window Is Premature
Alper and Brown
Stroke 2009;40:e632-e632.
FULL TEXT  

Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein
Suzuki et al.
Blood 2009;114:3352-3358.
ABSTRACT | FULL TEXT  

Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator: A Science Advisory From the American Heart Association/American Stroke Association
del Zoppo et al.
Stroke 2009;40:2945-2948.
FULL TEXT  

Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Lansberg et al.
Stroke 2009;40:2438-2441.
ABSTRACT | FULL TEXT  

Intravenous Thrombolysis for Acute Ischemic Stroke: Time Is Prime
Ingall
Stroke 2009;40:2264-2265.
FULL TEXT  

A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions
Mandava and Kent
Stroke 2009;40:1803-1810.
ABSTRACT | FULL TEXT  

Advances in Critical Care and Emergency Medicine
Mayer and Schwab
Stroke 2009;40:e298-e300.
FULL TEXT  

Outcomes of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 90 Years or Older
Mateen et al.
Mayo Clin Proc. 2009;84:334-338.
ABSTRACT | FULL TEXT  

Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke
Zivin et al.
Stroke 2009;40:1359-1364.
ABSTRACT | FULL TEXT  

Is It Ethical to Have a Placebo Arm in Reperfusion Trials in the 3- to 6-Hour Time Window?: Yes
Grotta and Barreto
Stroke 2009;40:1541-1542.
FULL TEXT  

Intra-Arterial Stroke Therapy: An Assessment of Demand and Available Work Force
Cloft et al.
Am. J. Neuroradiol. 2009;30:453-458.
ABSTRACT | FULL TEXT  

Existence of the Diffusion-Perfusion Mismatch within 24 Hours after Onset of Acute Stroke: Dependence on Proximal Arterial Occlusion
Copen et al.
Radiology 2009;250:878-886.
ABSTRACT | FULL TEXT  

Thrombolytic therapy with alteplase for ischaemic stroke
DTB 2009;47:14-18.
ABSTRACT | FULL TEXT  

Predictors of Hemorrhage Following Intra-Arterial Thrombolysis for Acute Ischemic Stroke: The Role of Pial Collateral Formation
Christoforidis et al.
Am. J. Neuroradiol. 2009;30:165-170.
ABSTRACT | FULL TEXT  

Thrombolysis 3 to 4.5 Hours after Acute Ischemic Stroke
Torbey et al.
NEJM 2008;359:2839-2841.
FULL TEXT  

Reperfusion-Associated Hemorrhagic Transformation in SHR Rats: Evidence of Symptomatic Parenchymal Hematoma
Henning et al.
Stroke 2008;39:3405-3410.
ABSTRACT | FULL TEXT  

Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)
Wahlgren et al.
Stroke 2008;39:3316-3322.
ABSTRACT | FULL TEXT  

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke et al.
NEJM 2008;359:1317-1329.
ABSTRACT | FULL TEXT  

Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
Hertzberg et al.
Clin Trials 2008;5:308-315.
ABSTRACT  

Thrombolysis for acute ischaemic stroke: a new challenge for emergency medicine
Kendall
Emerg. Med. J. 2008;25:471-475.
ABSTRACT | FULL TEXT  

Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes
Sato et al.
Neurology 2008;70:2371-2377.
ABSTRACT | FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Albers et al.
Chest 2008;133:630S-669S.
ABSTRACT | FULL TEXT  

Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review
Meseguer et al.
Age Ageing 2008;37:107-111.
FULL TEXT  

Acute Ischemic Stroke Treatment in 2007
Goldstein
Circulation 2007;116:1504-1514.
FULL TEXT  

Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience
Uyttenboogaart et al.
Age Ageing 2007;36:577-579.
FULL TEXT  

Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
De Keyser et al.
Stroke 2007;38:2612-2618.
ABSTRACT | FULL TEXT  

Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death
Arumugam et al.
Proc. Natl. Acad. Sci. USA 2007;104:14104-14109.
ABSTRACT | FULL TEXT  

Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome
Ringleb et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:690-693.
ABSTRACT | FULL TEXT  

Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study
Dirks et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:685-689.
ABSTRACT | FULL TEXT  

Size Matters: Hemorrhage Volume as an Objective Measure to Define Significant Intracranial Hemorrhage Associated With Thrombolysis
Christoforidis et al.
Stroke 2007;38:1799-1804.
ABSTRACT | FULL TEXT  

Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV)
The Optimising Analysis of Stroke Trials (OAST) Co
Stroke 2007;38:1911-1915.
ABSTRACT | FULL TEXT  

An Example of US Food and Drug Administration Device Regulation: Medical Devices Indicated for Use in Acute Ischemic Stroke
Pena et al.
Stroke 2007;38:1988-1992.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Adams et al.
Circulation 2007;115:e478-e534.
ABSTRACT | FULL TEXT  

Rapid Intracranial Clot Removal with a New Device: The Alligator Retriever
Kerber et al.
Am. J. Neuroradiol. 2007;28:860-863.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Adams et al.
Stroke 2007;38:1655-1711.
ABSTRACT | FULL TEXT  

Balloon Catheter Disruption of Middle Cerebral Artery Thrombus in Conjunction with Thrombolysis for the Treatment of Acute Middle Cerebral Artery Embolism
Ikushima et al.
Am. J. Neuroradiol. 2007;28:513-517.
ABSTRACT | FULL TEXT  

Intracranial Hemorrhage Associated With Revascularization Therapies
Khatri et al.
Stroke 2007;38:431-440.
ABSTRACT | FULL TEXT  

Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Kent et al.
Stroke 2006;37:2963-2969.
ABSTRACT | FULL TEXT  

The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Kent et al.
Stroke 2006;37:2957-2962.
ABSTRACT | FULL TEXT  

An Expedited Code Stroke Protocol Is Feasible and Safe
Sattin et al.
Stroke 2006;37:2935-2939.
ABSTRACT | FULL TEXT  

Characterizing physiological heterogeneity of infarction risk in acute human ischaemic stroke using MRI
Wu et al.
Brain 2006;129:2384-2393.
ABSTRACT | FULL TEXT  

Arteriographic Demonstration of Slow Antegrade Opacification Distal to a Cerebrovascular Thromboembolic Occlusion Site As a Favorable Indicator for Intra-Arterial Thrombolysis
Christoforidis et al.
Am. J. Neuroradiol. 2006;27:1528-1531.
ABSTRACT | FULL TEXT  

Analysis of Thrombi Retrieved From Cerebral Arteries of Patients With Acute Ischemic Stroke
Marder et al.
Stroke 2006;37:2086-2093.
ABSTRACT | FULL TEXT  

Early Recurrent Ischemic Stroke in Stroke Patients Undergoing Intravenous Thrombolysis
Georgiadis et al.
Circulation 2006;114:237-241.
ABSTRACT | FULL TEXT  

Thrombolysis (Tissue Plasminogen Activator) in Stroke: A Medicolegal Quagmire
Weintraub
Stroke 2006;37:1917-1922.
ABSTRACT | FULL TEXT  

Hemorrhage in the Interventional Management of Stroke Study
The IMS Study Investigators
Stroke 2006;37:847-851.
ABSTRACT | FULL TEXT  

Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials
Thomalla et al.
Stroke 2006;37:852-858.
ABSTRACT | FULL TEXT  

NXY-059: Review of Neuroprotective Potential for Acute Stroke
Fong and Rhoney
The Annals of Pharmacotherapy 2006;40:461-471.
ABSTRACT | FULL TEXT  

Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect
Kurth et al.
Am J Epidemiol 2006;163:262-270.
ABSTRACT | FULL TEXT  

Endovascular Recanalization Therapy in Acute Ischemic Stroke
Choi et al.
Stroke 2006;37:419-424.
ABSTRACT | FULL TEXT  

Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients: An Analysis of the Nationwide Inpatient Sample 1999 to 2002
Bateman et al.
Stroke 2006;37:440-446.
ABSTRACT | FULL TEXT  

Recruiting Subjects for Acute Stroke Trials: A Meta-Analysis
Elkins et al.
Stroke 2006;37:123-128.
ABSTRACT | FULL TEXT  

Internal Carotid Artery Stent Implantation in 25 Patients with Acute Stroke: Preliminary Results
Nedeltchev et al.
Radiology 2005;237:1029-1037.
ABSTRACT | FULL TEXT  

Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (>=80 Years) Stroke Patients
Berrouschot et al.
Stroke 2005;36:2421-2425.
ABSTRACT | FULL TEXT  

Intravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infarctions
Camerlingo et al.
Stroke 2005;36:2415-2420.
ABSTRACT | FULL TEXT  

Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
Palesch et al.
Stroke 2005;36:2410-2414.
ABSTRACT | FULL TEXT  

Clinical importance of microbleeds in patients receiving IV thrombolysis
Kakuda et al.
Neurology 2005;65:1175-1178.
ABSTRACT | FULL TEXT  

NIHSS Score and Arteriographic Findings in Acute Ischemic Stroke
Fischer et al.
Stroke 2005;36:2121-2125.
ABSTRACT | FULL TEXT  

Comparison of the National Institutes of Health Stroke Scale With Disability Outcome Measures in Acute Stroke Trials
Young et al.
Stroke 2005;36:2187-2192.
ABSTRACT | FULL TEXT  

"Clinical-CT Mismatch" and the Response to Systemic Thrombolytic Therapy in Acute Ischemic Stroke
Kent et al.
Stroke 2005;36:1695-1699.
ABSTRACT | FULL TEXT  

Initial Glasgow Coma Scale Score Predicts Outcome Following Thrombolysis for Posterior Circulation Stroke
Tsao et al.
Arch Neurol 2005;62:1126-1129.
ABSTRACT | FULL TEXT  

Safety and Efficacy of Mechanical Embolectomy in Acute Ischemic Stroke: Results of the MERCI Trial
Smith et al.
Stroke 2005;36:1432-1438.
ABSTRACT | FULL TEXT  

Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke
Savitz et al.
Stroke 2005;36:1447-1451.
ABSTRACT | FULL TEXT  

CT Sign of Brain Swelling without Concomitant Parenchymal Hypoattenuation: Comparison with Diffusion- and Perfusion-weighted MR Imaging
Na et al.
Radiology 2005;235:992-948.
ABSTRACT | FULL TEXT  

Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study
Hill et al.
CMAJ 2005;172:1307-1312.
ABSTRACT | FULL TEXT  

Mechanical Thrombectomy for Acute Stroke
Versnick et al.
Am. J. Neuroradiol. 2005;26:875-879.
ABSTRACT | FULL TEXT  

Markedly Reduced Apparent Blood Volume on Bolus Contrast Magnetic Resonance Imaging as a Predictor of Hemorrhage After Thrombolytic Therapy for Acute Ischemic Stroke
Alsop et al.
Stroke 2005;36:746-750.
ABSTRACT | FULL TEXT  

Is Thrombolytic Therapy Associated With Increased Mortality?: Meta-analysis of Randomized Controlled Trials
Ergin and Ergin
Arch Neurol 2005;62:362-366.
ABSTRACT | FULL TEXT  

Arterial Occlusion Revealed by CT Angiography Predicts NIH Stroke Score and Acute Outcomes after IV tPA Treatment
Sims et al.
Am. J. Neuroradiol. 2005;26:246-251.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging Criteria for Thrombolysis in Acute Cerebral Infarct
Hjort et al.
Stroke 2005;36:388-397.
ABSTRACT | FULL TEXT  

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
Hacke et al.
Stroke 2005;36:66-73.
ABSTRACT | FULL TEXT  

Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Pooled Analysis of Randomized Clinical Trials
Kent et al.
Stroke 2005;36:62-65.
ABSTRACT | FULL TEXT  

MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia
Pierre Gobin et al.
Stroke 2004;35:2848-2854.
ABSTRACT | FULL TEXT  

Management of Acute Ischemic Stroke
Fulgham et al.
Mayo Clin Proc. 2004;79:1459-1469.
ABSTRACT  

The probability of middle cerebral artery MRA flow signal abnormality with quantified CT ischaemic change: targets for future therapeutic studies
Barber et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:1426-1430.
ABSTRACT | FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Albers et al.
Chest 2004;126:483S-512S.
ABSTRACT | FULL TEXT  

Are There Time-Dependent Differences in Diffusion and Perfusion Within the First 6 Hours After Stroke Onset?
Fiehler et al.
Stroke 2004;35:2099-2104.
ABSTRACT | FULL TEXT  

Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases
Trouillas et al.
Stroke 2004;35:1323-1328.
ABSTRACT | FULL TEXT  

Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome
Weaver et al.
Stroke 2004;35:1216-1224.
ABSTRACT | FULL TEXT  

In Acute Ischemic Stroke, Are Asymptomatic Intracranial Hemorrhages Clinically Innocuous?
Kent et al.
Stroke 2004;35:1141-1146.
ABSTRACT | FULL TEXT  

Feasibility and safety of norepinephrine-induced arterial hypertension in acute ischemic stroke
Marzan et al.
Neurology 2004;62:1193-1195.
ABSTRACT | FULL TEXT  

Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study
The IMS Study Investigators
Stroke 2004;35:904-911.
ABSTRACT | FULL TEXT  

Effect of Incomplete (Spontaneous and Postthrombolytic) Recanalization After Middle Cerebral Artery Occlusion: A Magnetic Resonance Imaging Study
Neumann-Haefelin et al.
Stroke 2004;35:109-114.
ABSTRACT | FULL TEXT  

Assessment of the Patient with Hyperacute Stroke: Imaging and Therapy
Provenzale et al.
Radiology 2003;229:347-359.
ABSTRACT | FULL TEXT  

Effects of thrombolysis for acute stroke in patients with pre-existing disability
Foell et al.
CMAJ 2003;169:193-197.
ABSTRACT | FULL TEXT  

Selection of Acute Ischemic Stroke Patients for Intra-Arterial Thrombolysis With Pro-Urokinase by Using ASPECTS
Hill et al.
Stroke 2003;34:1925-1931.
ABSTRACT | FULL TEXT  

Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke
Higashida and Furlan
Stroke 2003;34 :e109-e137.
ABSTRACT | FULL TEXT  

Local Intra-arterial Fibrinolysis of Thromboemboli Occurring During Neuroendovascular Procedures With Recombinant Tissue Plasminogen Activator
Hahnel et al.
Stroke 2003;34:1723-1728.
ABSTRACT | FULL TEXT  

Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions
Arnold et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:739-742.
ABSTRACT | FULL TEXT  

Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke: Where Do We Go From Here? A Cumulative Meta-Analysis
Wardlaw et al.
Stroke 2003;34:1437-1442.
ABSTRACT | FULL TEXT  

Community-Based Thrombolytic Therapy of Acute Ischemic Stroke in Helsinki
Lindsberg et al.
Stroke 2003;34:1443-1449.
ABSTRACT | FULL TEXT  

Pre- and In-Hospital Delays From Stroke Onset to Intra-arterial Thrombolysis
Nedeltchev et al.
Stroke 2003;34:1230-1234.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association
Adams et al.
Stroke 2003;34:1056-1083.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.